New antibody drug targets autoimmune diseases in early trial

NCT ID NCT07229144

Recruiting now Disease control Sponsor: Ouro Medicines Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called OM336 in 39 adults with active Sjogren's disease or idiopathic inflammatory myopathy who have not improved with at least two prior treatments. OM336 is an engineered antibody designed to target and potentially reduce harmful immune cells. The main goal is to check safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OM336 (an engineered bispecific antibody targeting BCMA and CD3)
What this could lead to: If successful, this could point toward a new treatment option for people with active Sjogren's disease or idiopathic inflammatory myopathy who have not responded to other therapies.
What could go wrong: This is a very early (Phase 1b), small trial (39 participants) focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs do not advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic inflammatory myopathy myositis disease Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) SJOGRENS DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Waikato Hospital
RECRUITING

Hamilton, Waikato Region, 3204, New Zealand

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.